The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Rare Disease Treatment-Global Market Insights and Sales Trends 2024
Synopsis
A rare disease is any disease that affects a small percentage of the population.
The global Rare Disease Treatment market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Rare Disease Treatment in various end use industries. The expanding demands from the Hospital Pharmacies, Specialty Pharmacies and Retail Pharmacies,, are propelling Rare Disease Treatment market. Originator Drugs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Generic Drugs segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Rare Disease Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Rare Disease Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Rare Disease Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Rare Disease Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Rare Disease Treatment covered in this report include Novartis, Pfizer, F. Hoffmann-La Roche, Celgene, AbbVie, Johnson & Johnson, Takeda, Alexion and Novo Nordisk, etc.
The global Rare Disease Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis
Pfizer
F. Hoffmann-La Roche
Celgene
AbbVie
Johnson & Johnson
Takeda
Alexion
Novo Nordisk
Sanofi
Bayer
Amgen
Allergan
Eisai
Bristol-Myers Squibb
Merck
Vertex Pharmaceuticals
Baxter
BioMarin
Teva Pharmaceutical Industries
Global Rare Disease Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Rare Disease Treatment market, Segment by Type:
Originator Drugs
Generic Drugs
Global Rare Disease Treatment market, by Application
Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Rare Disease Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
A rare disease is any disease that affects a small percentage of the population.
The global Rare Disease Treatment market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Rare Disease Treatment in various end use industries. The expanding demands from the Hospital Pharmacies, Specialty Pharmacies and Retail Pharmacies,, are propelling Rare Disease Treatment market. Originator Drugs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Generic Drugs segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Rare Disease Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Rare Disease Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Rare Disease Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Rare Disease Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Rare Disease Treatment covered in this report include Novartis, Pfizer, F. Hoffmann-La Roche, Celgene, AbbVie, Johnson & Johnson, Takeda, Alexion and Novo Nordisk, etc.
The global Rare Disease Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis
Pfizer
F. Hoffmann-La Roche
Celgene
AbbVie
Johnson & Johnson
Takeda
Alexion
Novo Nordisk
Sanofi
Bayer
Amgen
Allergan
Eisai
Bristol-Myers Squibb
Merck
Vertex Pharmaceuticals
Baxter
BioMarin
Teva Pharmaceutical Industries
Global Rare Disease Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Rare Disease Treatment market, Segment by Type:
Originator Drugs
Generic Drugs
Global Rare Disease Treatment market, by Application
Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Rare Disease Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Rare Disease Treatment
1.1 Rare Disease Treatment Market Overview
1.1.1 Rare Disease Treatment Product Scope
1.1.2 Rare Disease Treatment Market Status and Outlook
1.2 Global Rare Disease Treatment Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Rare Disease Treatment Market Size by Region (2018-2029)
1.4 Global Rare Disease Treatment Historic Market Size by Region (2018-2023)
1.5 Global Rare Disease Treatment Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Rare Disease Treatment Market Size (2018-2029)
1.6.1 North America Rare Disease Treatment Market Size (2018-2029)
1.6.2 Europe Rare Disease Treatment Market Size (2018-2029)
1.6.3 Asia-Pacific Rare Disease Treatment Market Size (2018-2029)
1.6.4 Latin America Rare Disease Treatment Market Size (2018-2029)
1.6.5 Middle East & Africa Rare Disease Treatment Market Size (2018-2029)
2 Rare Disease Treatment Market by Type
2.1 Introduction
2.1.1 Originator Drugs
2.1.2 Generic Drugs
2.2 Global Rare Disease Treatment Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Rare Disease Treatment Historic Market Size by Type (2018-2023)
2.2.2 Global Rare Disease Treatment Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Rare Disease Treatment Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Rare Disease Treatment Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Rare Disease Treatment Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Rare Disease Treatment Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Rare Disease Treatment Revenue Breakdown by Type (2018-2029)
3 Rare Disease Treatment Market Overview by Application
3.1 Introduction
3.1.1 Hospital Pharmacies
3.1.2 Specialty Pharmacies
3.1.3 Retail Pharmacies
3.2 Global Rare Disease Treatment Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Rare Disease Treatment Historic Market Size by Application (2018-2023)
3.2.2 Global Rare Disease Treatment Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Rare Disease Treatment Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Rare Disease Treatment Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Rare Disease Treatment Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Rare Disease Treatment Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Rare Disease Treatment Revenue Breakdown by Application (2018-2029)
4 Rare Disease Treatment Competition Analysis by Players
4.1 Global Rare Disease Treatment Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Rare Disease Treatment as of 2022)
4.3 Date of Key Players Enter into Rare Disease Treatment Market
4.4 Global Top Players Rare Disease Treatment Headquarters and Area Served
4.5 Key Players Rare Disease Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Rare Disease Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Novartis
5.1.1 Novartis Profile
5.1.2 Novartis Main Business
5.1.3 Novartis Rare Disease Treatment Products, Services and Solutions
5.1.4 Novartis Rare Disease Treatment Revenue (US$ Million) & (2018-2023)
5.1.5 Novartis Recent Developments
5.2 Pfizer
5.2.1 Pfizer Profile
5.2.2 Pfizer Main Business
5.2.3 Pfizer Rare Disease Treatment Products, Services and Solutions
5.2.4 Pfizer Rare Disease Treatment Revenue (US$ Million) & (2018-2023)
5.2.5 Pfizer Recent Developments
5.3 F. Hoffmann-La Roche
5.3.1 F. Hoffmann-La Roche Profile
5.3.2 F. Hoffmann-La Roche Main Business
5.3.3 F. Hoffmann-La Roche Rare Disease Treatment Products, Services and Solutions
5.3.4 F. Hoffmann-La Roche Rare Disease Treatment Revenue (US$ Million) & (2018-2023)
5.3.5 Celgene Recent Developments
5.4 Celgene
5.4.1 Celgene Profile
5.4.2 Celgene Main Business
5.4.3 Celgene Rare Disease Treatment Products, Services and Solutions
5.4.4 Celgene Rare Disease Treatment Revenue (US$ Million) & (2018-2023)
5.4.5 Celgene Recent Developments
5.5 AbbVie
5.5.1 AbbVie Profile
5.5.2 AbbVie Main Business
5.5.3 AbbVie Rare Disease Treatment Products, Services and Solutions
5.5.4 AbbVie Rare Disease Treatment Revenue (US$ Million) & (2018-2023)
5.5.5 AbbVie Recent Developments
5.6 Johnson & Johnson
5.6.1 Johnson & Johnson Profile
5.6.2 Johnson & Johnson Main Business
5.6.3 Johnson & Johnson Rare Disease Treatment Products, Services and Solutions
5.6.4 Johnson & Johnson Rare Disease Treatment Revenue (US$ Million) & (2018-2023)
5.6.5 Johnson & Johnson Recent Developments
5.7 Takeda
5.7.1 Takeda Profile
5.7.2 Takeda Main Business
5.7.3 Takeda Rare Disease Treatment Products, Services and Solutions
5.7.4 Takeda Rare Disease Treatment Revenue (US$ Million) & (2018-2023)
5.7.5 Takeda Recent Developments
5.8 Alexion
5.8.1 Alexion Profile
5.8.2 Alexion Main Business
5.8.3 Alexion Rare Disease Treatment Products, Services and Solutions
5.8.4 Alexion Rare Disease Treatment Revenue (US$ Million) & (2018-2023)
5.8.5 Alexion Recent Developments
5.9 Novo Nordisk
5.9.1 Novo Nordisk Profile
5.9.2 Novo Nordisk Main Business
5.9.3 Novo Nordisk Rare Disease Treatment Products, Services and Solutions
5.9.4 Novo Nordisk Rare Disease Treatment Revenue (US$ Million) & (2018-2023)
5.9.5 Novo Nordisk Recent Developments
5.10 Sanofi
5.10.1 Sanofi Profile
5.10.2 Sanofi Main Business
5.10.3 Sanofi Rare Disease Treatment Products, Services and Solutions
5.10.4 Sanofi Rare Disease Treatment Revenue (US$ Million) & (2018-2023)
5.10.5 Sanofi Recent Developments
5.11 Bayer
5.11.1 Bayer Profile
5.11.2 Bayer Main Business
5.11.3 Bayer Rare Disease Treatment Products, Services and Solutions
5.11.4 Bayer Rare Disease Treatment Revenue (US$ Million) & (2018-2023)
5.11.5 Bayer Recent Developments
5.12 Amgen
5.12.1 Amgen Profile
5.12.2 Amgen Main Business
5.12.3 Amgen Rare Disease Treatment Products, Services and Solutions
5.12.4 Amgen Rare Disease Treatment Revenue (US$ Million) & (2018-2023)
5.12.5 Amgen Recent Developments
5.13 Allergan
5.13.1 Allergan Profile
5.13.2 Allergan Main Business
5.13.3 Allergan Rare Disease Treatment Products, Services and Solutions
5.13.4 Allergan Rare Disease Treatment Revenue (US$ Million) & (2018-2023)
5.13.5 Allergan Recent Developments
5.14 Eisai
5.14.1 Eisai Profile
5.14.2 Eisai Main Business
5.14.3 Eisai Rare Disease Treatment Products, Services and Solutions
5.14.4 Eisai Rare Disease Treatment Revenue (US$ Million) & (2018-2023)
5.14.5 Eisai Recent Developments
5.15 Bristol-Myers Squibb
5.15.1 Bristol-Myers Squibb Profile
5.15.2 Bristol-Myers Squibb Main Business
5.15.3 Bristol-Myers Squibb Rare Disease Treatment Products, Services and Solutions
5.15.4 Bristol-Myers Squibb Rare Disease Treatment Revenue (US$ Million) & (2018-2023)
5.15.5 Bristol-Myers Squibb Recent Developments
5.16 Merck
5.16.1 Merck Profile
5.16.2 Merck Main Business
5.16.3 Merck Rare Disease Treatment Products, Services and Solutions
5.16.4 Merck Rare Disease Treatment Revenue (US$ Million) & (2018-2023)
5.16.5 Merck Recent Developments
5.17 Vertex Pharmaceuticals
5.17.1 Vertex Pharmaceuticals Profile
5.17.2 Vertex Pharmaceuticals Main Business
5.17.3 Vertex Pharmaceuticals Rare Disease Treatment Products, Services and Solutions
5.17.4 Vertex Pharmaceuticals Rare Disease Treatment Revenue (US$ Million) & (2018-2023)
5.17.5 Vertex Pharmaceuticals Recent Developments
5.18 Baxter
5.18.1 Baxter Profile
5.18.2 Baxter Main Business
5.18.3 Baxter Rare Disease Treatment Products, Services and Solutions
5.18.4 Baxter Rare Disease Treatment Revenue (US$ Million) & (2018-2023)
5.18.5 Baxter Recent Developments
5.19 BioMarin
5.19.1 BioMarin Profile
5.19.2 BioMarin Main Business
5.19.3 BioMarin Rare Disease Treatment Products, Services and Solutions
5.19.4 BioMarin Rare Disease Treatment Revenue (US$ Million) & (2018-2023)
5.19.5 BioMarin Recent Developments
5.20 Teva Pharmaceutical Industries
5.20.1 Teva Pharmaceutical Industries Profile
5.20.2 Teva Pharmaceutical Industries Main Business
5.20.3 Teva Pharmaceutical Industries Rare Disease Treatment Products, Services and Solutions
5.20.4 Teva Pharmaceutical Industries Rare Disease Treatment Revenue (US$ Million) & (2018-2023)
5.20.5 Teva Pharmaceutical Industries Recent Developments
6 North America
6.1 North America Rare Disease Treatment Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Rare Disease Treatment Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Rare Disease Treatment Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Rare Disease Treatment Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Rare Disease Treatment Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Rare Disease Treatment Market Dynamics
11.1 Rare Disease Treatment Industry Trends
11.2 Rare Disease Treatment Market Drivers
11.3 Rare Disease Treatment Market Challenges
11.4 Rare Disease Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
